Positive Phase 3 Results for Novel Schizophrenia Drug

The investigational agent xanomeline-trospium (KarXT, Karuna Therapeutics), which combines a muscarinic receptor agonist with an anticholinergic agent, helps improve psychosis symptoms, and is not associated with weight gain or sedation in adults with schizophrenia, new research shows. Top-line results from the phase 3 EMERGENT-2 trial showed a significantly greater reduction from baseline on Positive and … Read more

Best Strategy to Prevent Schizophrenia Relapse Identified?

A large meta-analysis sheds light on the best antipsychotic maintenance strategy to prevent relapse in clinically-stable schizophrenia — with some unexpected results that have potential implications for changes to current guidelines. Consistent with the researchers’ hypothesis, continuing antipsychotic treatment at the standard dose, switching to another antipsychotic, and reducing the dose were all significantly more … Read more